Sibel Health, a spin-out of Northwestern University, announced the release of its physiological monitoring platform for clinical trial use dubbed Discovery alongside a partnership with AI-powered clinical trial solutions company Medidata.
The Illinois-based healthcare technology platform Discovery utilizes its FDA-cleared wearable sensors to monitor participants’ digital endpoints and vital signs during a clinical trial, including heart rate, blood pressure, SpO2, respiratory rate, and temperature.
Medidata, which offers AI-enabled digital solutions to support life sciences companies during clinical trials, will integrate Discovery into its cloud-based platform, allowing pharma companies and research organizations to access participants’ Sibel data.
“At Medidata, our unwavering commitment is to constantly redefine the boundaries of clinical research, all with the singular aim of expediting life-transforming treatments for patients,” Melissa Ceruolo, vice president of engineering and biomarker analytics at Medidata, said in a statement.
“By seamlessly integrating Sibel Health’s pioneering monitoring capabilities and digital endpoints into our expansive platform, we are arming researchers with unprecedented tools for groundbreaking discoveries. We are excited at the potential of this partnership to propel clinical trials forward and ultimately transform the practice of healthcare.”
THE LARGER TREND
In May, Sibel received FDA 510(k) clearance for its ANNE One platform continuous neonate and vital sign monitoring of infants born at any gestational age up to 2 years old.
The ANNE One platform allows for this vital sign monitoring via a clinical-grade wearable in two parts: the Anne limb, which measures skin and body temperature, and the Anne Chest, which monitors heart and respiratory rates, step count, fall count and skin temperature.
In August, the company raised $33 million in Series B funding, bringing its total raise to over $50 million.